File(s) not publicly available
Sitting less and moving more for improved metabolic and brain health in type 2 diabetes: ‘OPTIMISE your health’ trial protocol
journal contributionposted on 2022-09-29, 08:39 authored by Christian J. Brakenridge, P A Gardiner, R V Grigg, E A H Winkler, B S Fjeldsoe, M A Schaumberg, N Owen, E G Eakin, S J H Biddle, Marj MoodieMarj Moodie, Robin DalyRobin Daly, D J Green, N Cohen, L Gray, T Comans, M P Buman, A D Goode, Phuong NguyenPhuong Nguyen, Lan GaoLan Gao, G N Healy, David DunstanDavid Dunstan
Background: Clinical practice guidelines recommend that adults with type 2 diabetes (T2D) sit less and move more throughout the day. The 18-month OPTIMISE Your Health Clinical Trial was developed to support desk-based workers with T2D achieve these recommendations. The two-arm protocol consists of an intervention and control arms. The intervention arm receives 6 months health coaching, a sit-stand desktop workstation and an activity tracker, followed by 6 months of text message support, then 6 months maintenance. The control arm receives a delayed modified intervention after 12 months of usual care. This paper describes the methods of a randomised controlled trial (RCT) evaluating the effectiveness and cost-effectiveness of the intervention, compared to a delayed intervention control. Methods: This is a two-arm RCT being conducted in Melbourne, Australia. Desk-based workers (≥0.8 full-time equivalent) aged 35–65 years, ambulatory, and with T2D and managed glycaemic control (6.5–10.0% HbA1c), are randomised to the multicomponent intervention (target n = 125) or delayed-intervention control (target n = 125) conditions. All intervention participants receive 6 months of tailored health coaching assisting them to “sit less” and “move more” at work and throughout the day, supported by a sit-stand desktop workstation and an activity tracker (Fitbit). Participants receive text message-based extended care for a further 6-months (6–12 months) followed by 6-months of non-contact (12–18 months: maintenance). Delayed intervention occurs at 12–18 months for the control arm. Assessments are undertaken at baseline, 3, 6, 12, 15 and 18-months. Primary outcomes are activPAL-measured sitting time (h/16 h day), glycosylated haemoglobin (HbA1c; %, mmol/mol) and, cognitive function measures (visual learning and new memory; Paired Associates Learning Total Errors [adjusted]). Secondary, exploratory, and process outcomes will also be collected throughout the trial. Discussion: The OPTIMISE Your Health trial will provide unique insights into the benefits of an intervention aimed at sitting less and moving more in desk-bound office workers with T2D, with outcomes relevant to glycaemic control, and to cardiometabolic and brain health. Findings will contribute new insights to add to the evidence base on initiating and maintaining behaviour change with clinical populations and inform practice in diabetes management. Trial registration: ANZCTRN12618001159246.
JournalBMC Public Health
Read the peer-reviewed publication
Science & TechnologyLife Sciences & BiomedicinePublic, Environmental & Occupational HealthType 2 diabetesSedentary behaviourGlycaemic controlCognitive functionRANDOMIZED CONTROLLED-TRIALCONSENSUS SLEEP DIARYPHYSICAL-ACTIVITYOFFICE WORKERSSEDENTARY BEHAVIORPOSTPRANDIAL GLUCOSEALZHEIMERS-DISEASEACTIVITY MONITORPROBLEM AREASLOW-INCOME